department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Neurotech Pharmaceuticals Inc · pharmadog

PUBLIC COMPANY

Neurotech Pharmaceuticals Inc

updated 1mo ago

community read0 votes

pipeline

1

marketed

1

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Marketed

revakinagene taroretcel

Idiopathic Juxtafoveolar Retinal Telangiectasis (IJRT)

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Neurotech Pharmaceuticals Inc jobs →

News

no news has mentioned this company yet

identifiers

source

globaldata

top tags

mentioned in

0news items

entity-linker matched

Active trials

phase4Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participantsrecruitingn=285
phase3A Study to Determine the Safety and Efficacy of NT-501 With MHFMactive not recruitingn=12
phase2Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)completedn=70
phase2A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosacompletedn=73
phase2A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degenerationcompletedn=53
phase2Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2completedn=33
phase3A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol Bcompletedn=119
phase3A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol Acompletedn=120

more trials →

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?